This is a prospective, multi-center, controlled, randomized, pivotal study to evaluate the safety and effectiveness of the VitaSmart™ Liver Machine Perfusion System by comparing clinical outcomes in patients undergoing liver transplantation with ex-vivo liver preservation using static cold storage (SCS) followed by hypothermic oxygenated machine perfusion (HOPE) versus SCS only.
Patients on the UNOS waiting list for liver transplantation who have been consented, meet study eligibility criteria and are matched to a liver allograft from donation after brain death (DBD) or donation after circulatory death (DCD) that meet the extended risk eligibility criteria will be randomized 1:1 to SCS followed by HOPE (HOPE arm) or to SCS only (SCS arm). The objective of the study is to demonstrate the safety and effectiveness of the VitaSmart™ Liver Machine by comparing endpoints between the HOPE and SCS arms. Following transplantation, patients will be monitored daily (labs, adverse events, medications/procedures) while inpatient, and then additionally on Days 14 and 30 and Months 3, 6 and 12. The primary efficacy endpoint of early allograft dysfunction (EAD) rate will be assessed between HOPE and control using a non-inferiority design. An interim analysis is planned after approximately 70% of patients have been completed primary endpoint data collection to assess for early study completion based on non-inferiority or superiority.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
228
Following donor liver retrieval, preservation using static cold storage, and back table preparation in the transplant center operating room, the organ will be flushed with Belzer UW® Machine Perfusion Solution (MPS) and perfused through the cannulated portal vein using cold, actively oxygenated MPS that is circulated at low pressure for 90 minutes to 5 hours. After disconnection from the device, donor liver implantation and reperfusion will proceed in accordance with institutional care standards.
Donor liver retrieval and preservation using standard of care cold storage methods
Loma Linda University Medical Center
San Bernadino, California, United States
University of California San Francisco
San Francisco, California, United States
Early Allograft Dysfunction (EAD)
Proportion of participants with EAD by 7 days post-transplant (or at hospital discharge if prior to 7 days). Defined by the presence of one or more of the following outcomes: * Serum bilirubin ≥10 mg/dL at day 7 post-transplant * INR ≥1.6 at day 7 post-transplant * ALT or AST \>2000 IU/L within the first 7 days post-transplant
Time frame: 7 days
Graft Survival at 6 Months
Graft survival is defined as absence of death or graft failure
Time frame: 6 months following transplantation
Participant Survival at 6 Months
Participant survival is defined as absence of death.
Time frame: 6 months following transplantation
Graft Survival at 12 Months/30 Days
Graft survival is defined as absence of death or graft failure
Time frame: Up to 12 months following transplantation
Participant Survival at 12 Months/30 Days
Participant survival is defined as absence of death.
Time frame: Up to 12 months following transplantation
Model for Early Allograft Function (MEAF) Score
Model for Early Allograft Score (MEAF) is a continuous scoring system based on the subject's maximum labs within the first three days post transplant, alanine aminotransferase (ALT) and international normalized ratio (INR) plus day-3 bilirubin. The score ranges from 0-10 with 0 being the worst to 10 being the best and provides a grade for liver dysfunction severity.
Time frame: Within 3 days post-transplant
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Stanford University Medical Center
Stanford, California, United States
Mayo Clinic
Jacksonville, Florida, United States
Cleveland Clinic
Weston, Florida, United States
Indiana University
Indianapolis, Indiana, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Lahey Hospital and Medical Center
Burlington, Massachusetts, United States
Henry Ford Hospital
Detroit, Michigan, United States
Washington University St. Louis
St Louis, Missouri, United States
...and 5 more locations
Primary Non-function (PNF)
Defined as early graft failure resulting in re-transplantation or death with no hepatic artery thrombosis or other detectible technical complications and with AST≥3000 IU/L and either INR≥2.5, arterial pH≤7.30, venous pH≤7.25 or serum lactate≥4mmol/L
Time frame: Within 7 days post-transplant
Length of Hospital Stay
Duration from initial ICU or floor admission to hospital discharge order (measured in days)
Time frame: End of surgery to hospital discharge
Length of Intensive Care Unit Stay
Duration from initial intensive care unit (ICU) admission to ICU discharge order (measured in days), patients that did not go to ICU were assumed '0' days
Time frame: End of surgery to ICU discharge
Duration on Renal Replacement Therapy (RRT)
Includes patient that required RRT within 2 weeks post-transplantation; duration from until discontinuation of dialysis for \>2 weeks
Time frame: Post-transplantation until RRT discontinued for >2 weeks
Donor Liver Utilization
Defined as the proportion of randomized donor/recipients to transplanted recipients
Time frame: Randomization to transplantation
Biopsy-proven Liver Rejection
Rejections confirmed on biopsy were tabulated between the 2 groups.
Time frame: Up to 12 months following transplantation
Central Radiologist Diagnosed Non-anastomotic Strictures (NAS)
Non-anastomotic strictures (NAS) were diagnosed by the blinded, central radiologist on cholangiograms (ERCP, MRCP)
Time frame: Up to 12 months after transplantation
Unanticipated Adverse Device Effects (UADEs)
UADE is defined as an adverse event that is serious and device related. UADE reporting is only applicable to the HOPE arm.
Time frame: 12 months after transplantation